[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stricture-bowel\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stricture-bowel":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100627086","guselkumab-vs-ustekinumab-in-stricturing-crohns-disease-100627086",false,"NCT07444060","Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","Efficacy of Guselkumab Versus Ustekinumab in Stricturing Crohn's Disease: A Multicenter, Prospective, Observational Cohort Study","Inclusion Criteria:\n\n* Confirmed patients with moderate-to-severe Crohn's disease (CD), aged 18 to 80 years, receiving treatment with Guselkumab or Ustekinumab.\n* Presence of obstructive symptoms consistent with chronic or subacute intestinal obstruction within the past 8 weeks, with confirmed postprandial abdominal pain attributable to strictures, with the exclusion of: ① mild to moderate pain (postprandial abdominal pain or abdominal pain exacerbated by diet, ameliorated with abdominal bowel sounds) without nausea, vomiting or abdominal colic; ② dietary restrictions unrelated to abdominal pain.\n* Evidence of definite luminal strictures caused by the disease itself confirmed by radiographic imaging or endoscopic examination, i.e., meeting any of the following criteria:\n\n  1. Enteric computed tomography (CT): Presence of intestinal strictures on enteric CT, with two of the three following findings at the stricture site compared with the adjacent proximal bowel: ① a \\>50% reduction in luminal diameter; ② a \\>25% increase in bowel wall thickness; ③ pre-stenotic dilation \\>2.5 cm.\n  2. Endoscopic examination: Intestinal strictures that are impassable to the endoscope.\n\nExclusion Criteria:\n\n* Patients with severe disease requiring emergency surgery or endoscopic therapeutic intervention, or those judged by the attending clinician to need a switch of medication or elective surgery within 2 months, such as those with acute severe intestinal obstruction, perforation, intra-abdominal abscess, intra-abdominal adhesion, and other conditions leading to obstruction, hemorrhage, infection, etc.\n* Intestinal obstruction, intra-abdominal abscess, isolated intestinal stricture and other lesions secondary to surgery.\n* Patients who have received definitive therapeutic interventions for strictures within the past 6 months, such as endoscopic balloon dilation, stricture incision, intestinal stricture plasty, surgical\u002Fmanual anal dilatation, etc.\n* Severe patients who remain unable to take oral intake despite enteral nutrition (EN) administration for more than 2 months.\n* Patients who have used Guselkumab (GUS), Ustekinumab (UST) or other IL-23 antagonists within the past 12 months; or those with contraindications to GUS\u002FUST, or intolerance to the study medications due to other causes (e.g., allergy to IL-23 antagonists).\n* Patients with contraindications to small intestinal computed tomography (CT), such as contrast media allergy.\n* Patients with relative contraindications to biological agents, such as active tuberculosis with a positive chest X-ray for pulmonary tuberculosis or a strongly positive tuberculin skin test; a history of myocardial infarction, heart failure or demyelinating neurological diseases within the past 5 years.\n* Patients currently suffering from solid tumors, with a past history of lymphoma or melanoma, or undergoing chemotherapy or radiotherapy.\n* Patients complicated with intestinal dysplasia (e.g., diagnosed with short bowel syndrome), colostomy or colorectal neoplasms.\n* Patients complicated with active massive gastrointestinal hemorrhage, severe hepatic and renal dysfunction, active bacterial or viral infection, shock, as well as intractable vomiting and severe malabsorption syndrome.\n* Pregnant or lactating patients.\n* Patients with severe hemodynamic and vital sign instability, or those with rapidly progressive or end-stage diseases.\n* Patients with psychiatric disorders, or those with insufficient educational level to fully understand the study content or unable to cooperate with the completion of the study.","ALL","18 Years","80 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","This study intends to select patients with confirmed moderate-to-severe Crohn's disease (CD) and obstructive symptoms of intestinal stenosis, who have clear evidence of lumen stenosis caused by the disease itself through radiography or endoscopy. After the informed consent of the patients, comprehensive drug therapy with Guselkumab or Ustekinumab as the mainstay was performed. The basic information and medical history of the patients were collected, and the treatment process of the patients was followed up and recorded, and the drug regimen was adjusted according to the physician's experience and judgment. At different follow-up time points, blood, feces, tissue and other specimens of patients were collected according to the situation, and gastrointestinal endoscopy, imaging examination, laboratory index examination, self-assessment of subjects' symptoms, and nutritional risk screening were performed on the patients. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.",[25,26,27],"CD - Crohn's Disease","Stricture; Bowel","IBD - Inflammatory Bowel Disease",[29,30,31],"Stricturing Crohn's Disease","Guselkumab","Ustekinumab","RECRUITING","2026-02-25",{"date":35,"type":36},"2026-03-02","ACTUAL",{"date":38,"type":21},"2026-03-01",{"date":40,"type":21},"2029-12-31",{"name":42,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100468995","efficacy-of-ustekinumab-therapy-in-patients-with-symptomatic-stricturing-crohns-disease-100468995","NCT05387031","Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease","Efficacy of Ustekinumab-based Integrated Medicine Therapy in Patients With Symptomatic Stricturing Crohn's Disease: a Multicenter, Prospective, Observational Cohort Study","Inclusion Criteria:\n\n* Clinical diagnosis of moderate to severe Crohn's disease\n* Obstructive symptoms within the last eight weeks\n* A single or several lumen stricture(s) identified by radiological imaging or endoscopy\n* For strictures identified by CT enterograph defined as a lesion with combination of a reduction of luminal narrowing \\>50%, an increase in bowel wall thickness \\>25% relative to non-affected bowel and pre-stricture dilation \\>3.0 cm\n* For strictures identified during endoscopic procedure defined by intestinal strictures with a lumen diameter ≤12 mm or even inability to pass the endoscope across the narrowing\n\nExclusion Criteria:\n\n* Requirement of urgent surgery or endoscopic intervention within 2 months as judged by the clinician\n* Symptoms or signs of perforation such as active perianal sepsis, abdominal abscess, intestinal fistula, and abdominal adhesions\n* Intestinal obstruction caused by surgery, intra-abdominal abscess, isolated intestinal stricture\n* Effective treatments for stricture in the past half a year, such as endoscopic balloon dilatation, intestinal stricture plasty, surgery\u002Fmanual anal dilatation, etc.\n* Unable to eat after using enteral nutrition for more than 2 months\n* History of ustekinumab (UST) or other IL-23 antagonists use in the past 12 months\n* CT enterograph contraindications, such as allergy to contrast media\n* Relative contraindications of biological agents, such as pulmonary tuberculosis-positive chest X-ray or active tuberculosis with strong positive tuberculin skin test, myocardial infarction, heart failure, or demyelinating neurological disease\n* Currently suffering from a solid tumor, lymphoma, or melanoma and undergoing chemotherapy or radiation therapy\n* Combination of intestinal dysplasia (eg, diagnosed with short bowel syndrome), colostomy, or colorectal tumors\n* Combination of active gastrointestinal bleeding, shock, severe diarrhea, refractory vomiting and severe malabsorption syndrome\n* Combination of severe liver and kidney dysfunction\n* Coexistence of bacterial or viral active infection\n* Pregnant or breastfeeding\n* Severe hemodynamics, unstable vital signs or presence of rapidly progressive or end-stage disease, expected to be fatal during the course of the study","65 Years",{"count":54,"type":21},239,"This study intends to select patients with confirmed moderate-to-severe Crohn's disease (CD) and obstructive symptoms of intestinal stenosis, who have clear evidence of lumen stenosis caused by the disease itself through radiography or endoscopy. After the informed consent of the patients, comprehensive drug therapy with ustekinumab as the mainstay was performed. The basic information and medical history of the patients were collected, and the treatment process of the patients was followed up and recorded, and the drug regimen was adjusted according to the physician's experience and judgment. At different follow-up time points, blood, feces, tissue and other specimens of patients were collected according to the situation, and gastrointestinal endoscopy, imaging examination, laboratory index examination, self-assessment of subjects' symptoms, and nutritional risk screening were performed on the patients. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.",[57,26,58],"Crohn Disease","Intestinal Stricture",[57,60,31,61,62],"intestinal stricture","integrated medicine therapy","cohort study",{"date":64,"type":36},"2026-02-27",{"date":66,"type":36},"2024-08-01",{"date":68,"type":21},"2028-08-01",{"name":42,"class":43},8,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100571846","endoscopically-placed-lumen-apposing-metal-stents-for-the-treatment-of-symptomatic-intestinal-strictures-in-individuals-with-inflammatory-bowel-disease-100571846","NCT06725563","Endoscopically Placed Lumen-Apposing Metal Stents for the Treatment of Symptomatic Intestinal Strictures in Individuals With Inflammatory Bowel Disease","Endoscopically Placed Lumen-Apposing Metal Stents as a Safe Alternative to Surgery for the Treatment of Symptomatic Intestinal Strictures in Individuals With Inflammatory Bowel Disease","Inclusion Criteria:\n\n* ≥18 years of age\n* Established Diagnosis of inflammatory bowel disease\n* Symptomatic, single, fibrostenotic or anastomotic stricture \\<6 cm in length without severe active inflammation, pre-stenotic intestinal fistula or penetrating complication, and within reach of the adult colonoscope (colon or terminal ileum)\n* Ability to accurately gauge stricture length with imaging and safely deploy the stent using conventional fluoroscopic techniques\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* More than one intestinal stricture\n* Stricture out of reach of standard adult colonoscope\n* High-grade stricture (complete or near complete bowel obstruction\n* Severe active inflammation in the stricture or associated penetrating complication, including fistula, inflammatory phlegmon or abscess\n* Contraindications for endoscopic therapy, including:\n* Complete Bowel obstruction\n* Severe cardiorespiratory comorbidity\n* Unable to tolerate sedation or anesthesia\n* Non-reversible coagulopathy",{"count":79,"type":21},20,"INTERVENTIONAL",[82],"NA","This is a single-center prospective pilot study in patients with symptomatic partially obstructing intestinal strictures without severe active inflammation or penetrating complications, evaluating the use of LAMS with respect to symptom and quality of life improvement and the development of stent-related complications.",[85,26],"Inflammatory Bowel Diseases","NOT_YET_RECRUITING","2024-12-04",{"date":89,"type":36},"2024-12-10",{"date":91,"type":21},"2025-01-01",{"date":93,"type":21},"2026-12-31",{"name":95,"class":43},"Ottawa Hospital Research Institute"]